Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for cardiometabolic diseases.
The collaboration is valued up to $354m, but financial specifics remain undisclosed. The companies aim to advance precision drug delivery by leveraging Gensaic鈥檚 AI-guided ligand discovery platform. Novo and Gensaic did not say which specific cardiometabolic conditions they are targeting.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Tissue targeting is a key focus in drug development, as it allows therapies to be delivered directly to specific organs or cell types rather than affecting the entire body. This precision can enhance drug effectiveness while minimising side effects. However, targeting tissues beyond the liver remains a challenge, limiting the reach of many existing therapies, Gensaic said in the 3 March announcement.
Gensaic鈥檚 platform, dubbed FORGE, is designed to address this issue by identifying protein ligands that enable selective delivery of therapeutic molecules, potentially unlocking new treatment options for cardiometabolic diseases.
鈥淭issue targeting has so much potential 鈥� both in terms of the modalities that can be leveraged, but also for the diseases that can be addressed,鈥� said Uli Stilz, head of Novo鈥檚 bio innovation hub.
The FORGE platform combines AI-driven protein design with laboratory-based protein evolution to discover new ligands 鈥� molecules that bind to specific targets in the body. By mapping and optimising protein interactions, the platform aims to identify ligands that can transport drugs into specific tissues. This approach could enable the targeted delivery of a range of therapeutic molecules, including small interfering RNA (siRNA), which is used to regulate gene expression in diseases.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSeveral biotech companies are exploring tissue-targeting approaches to improve drug delivery. Alnylam 色界吧s has developed GalNAc conjugates such as Amvuttra (vutrisiran), which enable targeted delivery of RNA-based drugs specifically to liver cells. Similarly, Arrowhead 色界吧s has advanced its targeted RNAi molecule (TRiM) platform to enhance the delivery of RNAi therapies to tissues beyond the liver, including the lungs and muscles.
Novo Nordisk is an established leader in the cardiometabolic space and has secured several deals in the past few years to maintain its dominant position in this market. In September 2024, the company signed a $600m deal with NanoVation to develop genetic medicines for rare and cardiometabolic diseases. As part of the agreement, Novo secured a licence to use NanoVation鈥檚 long-circulating lipid nanoparticle (lcLNP) technology for RNA delivery targeting cells outside the liver.
